Literature DB >> 20864270

Helical tomotherapy versus conventional intensity-modulated radiation therapy for primary chemoradiation in cervical cancer patients: an intraindividual comparison.

Simone Marnitz1, Dusko Lukarski, Christhardt Köhler, Waldemar Wlodarczyk, Andreas Ebert, Volker Budach, Achim Schneider, Carmen Stromberger.   

Abstract

PURPOSE: To compare intensity-modulated radiotherapy (IMRT) delivered by helical tomotherapy (HT) with conventional IMRT for primary chemoradiation in cervical cancer patients. METHODS AND MATERIALS: Twenty cervical cancer patients undergoing primary chemoradiation received radiation with HT; 10 patients underwent pelvic irradiation (PEL) and 10 extended-field irradiation (EXT). For treatment planning, the simultaneously integrated boost (SIB) concept was applied. Tumor, pelvic, with or without para-aortic lymph nodes were defined as planning target volume A (PTV-A) with a prescribed dose of 1.8/50.4 Gy (28 fractions). The SIB dose for the parametrium (PTV-B), was 2.12/59.36 Gy. The lower target constraints were 95% of the prescribed dose in 95% of the target volume, and the upper dose constraint was 107%. The irradiated small-bowel volumes were kept as low as possible. For every HT plan, a conventional IMRT plan was calculated and compared with regard to dose-volume histogram, conformity index and conformity number, and homogeneity index.
RESULTS: Both techniques allowed excellent target volume coverage and sufficient SB sparing. Conformity index and conformity number results for both PTV-A and PTV-B, homogeneity index for PTV-B, and SB sparing for V45, V50, Dmax, and D1% were significantly better with HT. SB sparing was significantly better for conventional IMRT at low doses (V10).
CONCLUSIONS: Both HT and conventional IMRT provide optimal treatment of cervical cancer patients. The HT technique was significantly favored with regard to target conformity, homogeneity, and SB sparing. Randomized trials are needed to assess the oncological outcome, toxicity, and clinical relevance of these differences.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20864270     DOI: 10.1016/j.ijrobp.2010.06.005

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  15 in total

Review 1.  Volumetric modulated arc therapy: a review of current literature and clinical use in practice.

Authors:  M Teoh; C H Clark; K Wood; S Whitaker; A Nisbet
Journal:  Br J Radiol       Date:  2011-11       Impact factor: 3.039

2.  Short term outcomes of helical tomotherapy during concurrent chemoradiotherapy for advanced cervical cancer.

Authors:  Yasushi Mabuchi; Yoshihiro Takiguchi; Tamaki Yahata; Mika Mizoguchi; Noriyuki Sasaki; Nami Ota; Sawako Minami; Kazuhiko Ino
Journal:  Mol Clin Oncol       Date:  2019-01-23

3.  Variability in clinical target volume delineation for intensity modulated radiation therapy in 3 challenging cervix cancer scenarios.

Authors:  Karen Lim; Beth Erickson; Ina M Jürgenliemk-Schulz; David Gaffney; Carien L Creutzberg; Akila Viswanathan; Lorraine Portelance; Sushil Beriwal; Aaron Wolfson; Walter Bosch; Jennifer De Los Santos; Catheryn Yashar; Anuja Jhingran; Mahesh Varia; Issam El Naqa; Bronwyn King; Anthony Fyles
Journal:  Pract Radiat Oncol       Date:  2015-07-02

4.  Adjuvant radiochemotherapy in patients with locally advanced high-risk cervical cancer.

Authors:  F Heinzelmann; G Henke; M von Grafenstein; N Weidner; F Paulsen; A Staebler; S Brucker; M Bamberg; M Weinmann
Journal:  Strahlenther Onkol       Date:  2012-05-23       Impact factor: 3.621

5.  Adjuvant chemoradiation after laparoscopically assisted vaginal radical hysterectomy (LARVH) in patients with cervical cancer: oncologic outcome and morbidity.

Authors:  Arne Gruen; Thabea Musik; Christhardt Köhler; Jürgen Füller; Thomas Wendt; Carmen Stromberger; Volker Budach; Achim Schneider; Simone Marnitz
Journal:  Strahlenther Onkol       Date:  2011-05-16       Impact factor: 3.621

6.  Patterns of care in patients with cervical cancer 2012: results of a survey among German radiotherapy departments and out-patient health care centers.

Authors:  S Marnitz; C Köhler; A Rauer; A Schneider; V Budach; A Tsunoda; M Mangler
Journal:  Strahlenther Onkol       Date:  2013-07-27       Impact factor: 3.621

7.  Aspects of Therapy for Cervical Cancer in Germany 2012 - Results from a Survey of German Gynaecological Hospitals.

Authors:  M Mangler; N Zech; A Schneider; C Köhler; S Marnitz
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-03       Impact factor: 2.915

8.  Treatment Outcome of the Combination Therapy of High-dose rate Intracavitary Brachytherapy and Intensity-modulated Radiation Therapy With Central-shielding for Cervical Cancer.

Authors:  Yuki Mukai; Yumiko Minagawa; Hiromi Inoue; Akiko Sato; Kengo Matsui; Takanori Fukuda; Kazuya Onuma; Hideyuki Hongo; Ryosuke Shirata; Hironori Nagata; Harumitu Hashimoto; Tomio Inoue; Masaharu Hata; Motoko Omura
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

9.  Optimizing image guidance frequency and implications on margins for gynecologic malignancies.

Authors:  Carmen Stromberger; Arne Gruen; Waldemar Wlodarczyk; Volker Budach; Christhardt Koehler; Simone Marnitz
Journal:  Radiat Oncol       Date:  2013-05-02       Impact factor: 3.481

10.  Retrospective feasibility study of simultaneous integrated boost in cervical cancer using Tomotherapy: the impact of organ motion and tumor regression.

Authors:  Fernanda G Herrera; Sharon Callaway; Ela Delikgoz-Soykut; Mehtap Coskun; Laetitia Porta; Jean-Yves Meuwly; Joao Soares-Rodrigues; Leonie Heym; Raphael Moeckli; Mahmut Ozsahin
Journal:  Radiat Oncol       Date:  2013-01-03       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.